Hydrix Limited (AU:HYD) has released an update.
Hydrix Limited reported a challenging quarter with a 36% revenue drop, citing difficulty in securing venture capital and budget approvals for their medical device projects. Despite this, they boast a promising $300m pipeline with significant international presence, particularly in medtech growth areas. The company is actively managing costs and exploring funding options to navigate the fluid business landscape and support working capital requirements.
For further insights into AU:HYD stock, check out TipRanks’ Stock Analysis page.
